Sol-Gel Technologies (SLGL) Income towards Parent Company (2017 - 2026)

Sol-Gel Technologies' (SLGL) quarterly Income towards Parent Company came in at $3.7 million in Q1 2026, down 57.69% year-on-year from $8.8 million in Q1 2025, and up 106.02% on a QoQ basis from -$61.9 million in Q4 2025.

Sol-Gel Technologies (SLGL) Income towards Parent Company (2017 - 2026) Analysis & Trends

Sol-Gel Technologies (SLGL) has 10 years of Income towards Parent Company data on file, last reported at $3.7 million in Q1 2026.

  • On a quarterly basis, Income towards Parent Company fell 57.69% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was -$53.2 million, a 15.04% decrease from a year earlier, with the FY2025 full-year figure at -$66.0 million, down 6.86% from the prior year.
  • Income towards Parent Company for Q1 2026 stood at $3.7 million, up from -$61.9 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for SLGL reached as high as $11.2 million in Q2 2025 and fell as low as -$61.9 million in Q4 2025.
  • Historically, Income towards Parent Company has averaged -$10.8 million across 5 years, with a median of $134000.0 in 2022.
  • Across the five-year window, Income towards Parent Company surged 4355.22% in 2023 and tumbled 659.42% in 2025, its largest moves.
  • Year by year, Income towards Parent Company stood at -$50.9 million in 2022, then slipped by 4.75% to -$53.3 million in 2023, then retreated by 4.82% to -$55.9 million in 2024, then decreased by 10.78% to -$61.9 million in 2025, then jumped by 106.02% to $3.7 million in 2026.
  • Per Business Quant data, the three most recent Income towards Parent Company figures were $3.7 million in Q1 2026, -$61.9 million in Q4 2025, and -$6.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Sol-Gel Technologies 234.04 Mn 223.91 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 3.73 Mn
Dec 31, 2025 -61.92 Mn
Sep 30, 2025 -6.29 Mn
Jun 30, 2025 11.23 Mn
Mar 31, 2025 8.81 Mn
Dec 31, 2024 -55.89 Mn
Sep 30, 2024 -828,000.00
Jun 30, 2024 1.62 Mn
Mar 31, 2024 6.34 Mn
Dec 31, 2023 -53.32 Mn
Sep 30, 2023 -5.71 Mn
Jun 30, 2023 5.97 Mn
Mar 31, 2023 10.72 Mn
Dec 31, 2022 -50.90 Mn
Sep 30, 2022 -3.41 Mn
Jun 30, 2022 134,000.00
Mar 31, 2022 5.60 Mn
Dec 31, 2021 13.55 Mn
Sep 30, 2021 1.27 Mn
Jun 30, 2021 8.03 Mn